One of the most commonly sited uses for medical cannabis is eye health, namely glaucoma. But does it actually work?
As it turns out, the science behind that medical claim is, at best, promising but not concrete. Also, did you know that the levels of THC in European cannabis has doubled over the last 10 years? And have you heard how often fibromyalgia patients are misdiagnosed? All that and more in this week’s Medical Cannabis Weekly Review and Newsletter.
As always, you can get our weekly digest directly to your inbox, by subscribing to our weekly newsletter, below:
Eyes are the window to the soul, the lamp to the body, and our own personal portals to the outside world. Although we don’t actively think about the process of “seeing”, it’s something we do from the moment we open our eyes at birth. And it’s something that’s readily noticed (and particularly worrisome) when there is some sort of visionary malfunction.
Vision disorders, like glaucoma, are among of the most common uses for medical cannabis and was once a condition that had federal government approval for “compassionate marijuana use”. But is there any science to back up this claim? Let’s take a look.
Must Read Articles:
Outspoken Israel entrepreneur Clifton Flack has lost faith in medical cannabis and believes the future is CBD. Speaking at the Hemp & CBD Expo at Birmingham, England, he told CBD Testers: “The numbers don’t stack up for medical cannabis.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) report shows that the THC concentration of ‘herbal cannabis’ doubled from 5% to 10%, from 2006 to 2016, whilst cannabis resin potency increased from 8% to 17% over the same period.
According to a new study from Arthritis Care & Research, the agreement between physicians’ diagnosis of fibromyalgia and the published criteria is only moderate. The study stated that, in total, physicians incorrectly identified 11.4 percent of patients who were criteria-negative and failed to diagnose 49.6 percent of criteria-positive patients.
Other Trending News:
- U.S. to spend $3 million to find out if CBD can relieve pain
- After the Summer of White Claw, CBD Water Is Making Its Move
- CBD Partnership Focuses on Quality, Purity of Ingredients
- Doctors slow to embrace treatments with cannabis
- Syqe Medical, TerrAscend to Distribute Medical Cannabis Inhaler to Canadian Market
- Medical cannabis product approved for epilepsy